Today's Scottish green light for the chemotherapy drug means the same key treatments for advanced prostate cancer are now routinely available to eligible men in all the home nations.
Men living in the two home nations with prostate cancer that's spread to the bones will now be able to access the life-enhancing treatment on the NHS if they're unable to have chemotherapy, thanks to reversal of a decision in 2015.
Eligible men in Wales with newly diagnosed advanced prostate cancer will now be offered earlier access to docetaxel chemotherapy alongside hormone therapy. Combining these treatments has been shown to offer these men the possibility of an extra fifteen months of life on average.
After months of consultation and negotiation, the proposed changes to the Cancer Drugs Fund come into effect. But do they go far enough for men with prostate cancer?
Today’s approval of the hormone therapy, degarelix, by NICE expands on the decision made in 2014 to make it only available to those men who have already developed the symptoms of spinal cord compression. Now, men whose prostate cancer has spread to their spine and who could be at risk of this condition can also access this treatment.
Cabazitaxel chemotherapy has been rejected by the Scottish Medicines Consortium (SMC) for routine use on the NHS in Scotland, it has been announced today.
NICE's welcome decision follows a reappraisal involving new data and a price cut by the drug's manufacturer, but lengthy negotiations should be avoided in future.
Following 18 months of lobbying NICE and the drug's manufacturer, abiraterone will now be made routinely available on the NHS to men with prostate cancer - whether or not they've had chemotherapy.
Treatment for advanced prostate cancer approved for use in Scotland for men who have not yet had chemotherapy.
BLOG: Our Director of Support and Influencing, Heather Blake, explains why NHS England's proposed reforms to the Cancer Drugs Fund put them in a financial standoff with Big Pharma, while men with prostate cancer are caught in the middle.